Search Results
Results found for "Chris Evans"
- Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair
Chronic human HF is characterized by several important neurohormonal perturbations, emanating from both
- Asking Better Questions in Science: A Practical Guide for Emerging Researchers
Yet one well-timed question can unlock clarity, accelerate a stalled project, or even spark a collaboration
- Conjugation Strategies for Probe Development
NHS esters are not very stable even in aqueous environment but they only need a slightly basic medium
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
therapeutic window â Examples of how rebinding in dense receptor environments  amplifies target occupancy, even
- How Fast Does a Drug Work?
a ligand binds (kâ) and how long it stays bound (kâ) Â can alter therapeutic profiles dramatically, even
- Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!
We've got 11 GPCR papers, seven industry news pieces, a new GPCR event, and even a job ad. Â
- Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells
It can even study the GPCR distribution within endocytic vesicles and across subcellular compartments
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
Ligands may take hours to equilibrate , even when they look potent on paper.
- Integrated GPCR Drug Discovery: A Structured Framework for Modern Programs
dynamics simulations accelerate hypothesis generation, disciplined experimental confirmation becomes even
- Early Safety Assays: Identifying Showstoppers in GPCR Drug Discovery Pipelines Early
The pressure mounts further as regulators require detection and characterization of these liabilitiesâeven
- The Hidden Operating Cadence Thatâs Actually Driving Your Biotech
. đ The CEO becomes the unofficial project manager , even if they believe theyâre âempowering the team
- How System-Level GPCR Thinking Prevents Discovery Failures
Gain Spot false confidence early  â Sensitivity differences can turn full agonists into partials or even
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
The Future of GPCR Therapeutics in Metabolic Disease Even with GLP-1 and GIP agonists reshaping diabetes
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
microscopy-heavy workflows with no-wash, live-cell TRF detection Empower high-throughput internalization studies, even
- GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors
. đĄÂ Why This Matters â Even If Youâre Not a GPCR Scientist GPCR pathways intersect with oncology, CNS
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
your science isn't continuously integrated with your GPCR operational strategy and investment goals, even
- GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026
GPCR Podcast: When GPCR Tools Scale Even the most elegant tools only matter when they scale beyond a
- When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue
The Moment GPCR Imaging Became a Turning Point Before the islet lit up, the collaboration wasnât even
- Predicting GPCR Function: Inside the Carlsson Labâs Modeling Toolbox
Yet even with the structural biology revolution, one stubborn hurdle persists: prediction. Â
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
Itâs about how moments of redirection â even disappointment â can open new paths to impact.
- Your GPCR Program Decisions Depend on Good Data Interpretation
But Terry Kenakinâs new Emerging Drug Hunter lecture reveals why this assumption can mislead even experienced
- Amylin Receptor Signaling: Three Receptors From One, and How to Profile Each
favors cAMP over ÎČ-arrestin, or the reverse, can produce a meaningfully different functional outcome even
- Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling
Surprisingly, this interaction did not result in G12 activation, even in the presence of GTP, which is
- A Note from Yamina: Building the Next Chapter of Dr. GPCR
This year, we hosted in-person Happy Hours in Boston  (one even sponsored!)
- Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research
This means that even if one of the ligands they are bound to is promiscuous, it will not compromise assay
- Quantifying Receptor Selectivity in Modern Drug Discovery
A low-efficacy agonist tested in a low-sensitivity system may show no visible responseâeven at concentrations
- Extracellular signal-regulated kinases â a potential pathway for GPCR-targeted drug discovery
The gravity of this regulation becomes even more apparent when we consider the potential consequences
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
. â Why adjusting system sensitivity  can uncover hidden efficacy, silent antagonism, or even inverse
- Advantages of Fluorescent Probes in GPCR Assays
At Celtarys, we focus on developing fluorescent tools that keep minimal background signal even without
- Therapeutic validation of an orphan G proteinâcoupled receptor
Some studies have also reported GPR84 involvement in pain, atherosclerosis, and even metabolic disorders


























